Drug Profile


Alternative Names: 9-aminoacridine; Atabrine dihydrochloride; CBL 0102; Curaxin CBL0102; Quinacrine; SN 390

Latest Information Update: 23 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cleveland BioLabs
  • Developer Incuron; National Cancer Institute (USA)
  • Class Aminoacridines; Antimalarials; Antineoplastics; Antiprotozoals; Small molecules
  • Mechanism of Action SSRP1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I Liver cancer; Liver metastases; Non-small cell lung cancer

Most Recent Events

  • 23 May 2016 Mepacrine is still in phase I trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)
  • 23 May 2016 Phase-I development for Liver cancer and Liver metastases is ongoing in Russia (PO)
  • 23 May 2016 Phase-II development for Prostate cancer (Hormone refractory) is ongoing in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top